1
Weinberg RA. The biology of cancer. 2nd ed. New York: : Garland Science 2014.
2
Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell 2000;100:57–70. doi:10.1016/S0092-8674(00)81683-9
3
Lazebnik Y. What are the hallmarks of cancer? Nature Reviews Cancer 2010;10:232–3. doi:10.1038/nrc2827
4
Jeggo PA, Pearl LH, Carr AM. DNA repair, genome stability and cancer: a historical perspective. Nature Reviews Cancer 2015;16:35–42. doi:10.1038/nrc.2015.4
5
Roos WP, Thomas AD, Kaina B. DNA damage and the balance between survival and death in cancer biology. Nature Reviews Cancer 2015;16:20–33. doi:10.1038/nrc.2015.2
6
Shankaran V, Ikeda H, Bruce AT, et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107–11. doi:10.1038/35074122
7
Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903–7. doi:10.1038/nature06309
8
Hodi FS, O’Day SJ, McDermott DF, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine 2010;363:711–23. doi:10.1056/NEJMoa1003466
9
Robert D. Schreiber, Lloyd J. Old and Mark J. Smyth. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion. Science 2011;331:1565–70.http://www.jstor.org/stable/29783923?seq=1#page_scan_tab_contents
10
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. New England Journal of Medicine 2012;366:2443–54. doi:10.1056/NEJMoa1200690
11
Grupp SA, Kalos M, Barrett D, et al. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia. New England Journal of Medicine 2013;368:1509–18. doi:10.1056/NEJMoa1215134
12
Robbins PF, Morgan RA, Feldman SA, et al. Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. Journal of Clinical Oncology 2011;29:917–24. doi:10.1200/JCO.2010.32.2537
13
Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69–74. doi:10.1126/science.aaa4971
14
Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nature Medicine 2016;22:26–36. doi:10.1038/nm.4015
15
Morris EC, Stauss HJ. Optimizing T-cell receptor gene therapy for hematologic malignancies. Blood 2016;127:3305–11. doi:10.1182/blood-2015-11-629071
16
de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. The Lancet Oncology 2012;13:607–15. doi:10.1016/S1470-2045(12)70137-7
17
zur Hausen H. Papillomaviruses in the causation of human cancers — a brief historical account. Virology 2009;384:260–5. doi:10.1016/j.virol.2008.11.046
18
Ajila V, Shetty H, Babu S, et al. Human Papilloma Virus Associated Squamous Cell Carcinoma of the Head and Neck. Journal of Sexually Transmitted Diseases 2015;2015:1–5. doi:10.1155/2015/791024
19
Spurgeon ME, Lambert PF. Merkel cell polyomavirus: A newly discovered human virus with oncogenic potential. Virology 2013;435:118–30. doi:10.1016/j.virol.2012.09.029
20
Wendzicki JA, Moore PS, Chang Y. Large T and small T antigens of Merkel cell polyomavirus. Current Opinion in Virology 2015;11:38–43. doi:10.1016/j.coviro.2015.01.009
21
Schinzari V, Barnaba V, Piconese S. Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. Clinical Microbiology and Infection 2015;21:969–74. doi:10.1016/j.cmi.2015.06.026
22
Lingyun Geng. Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments. International Journal of Clinical and Experimental Medicine 2015;8.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658837/
23
Weiss RA, Vogt PK. 100 years of Rous sarcoma virus. The Journal of Experimental Medicine 2011;208:2351–5. doi:10.1084/jem.20112160
24
Matsuoka M, Jeang K-T. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene 2011;30:1379–89. doi:10.1038/onc.2010.537
25
Pierangeli A, Antonelli G, Gentile G. Immunodeficiency-associated viral oncogenesis. Clinical Microbiology and Infection 2015;21:975–83. doi:10.1016/j.cmi.2015.07.009
26
Reichert JM. Antibodies to watch in 2017. mAbs 2017;9:167–81. doi:10.1080/19420862.2016.1269580
27
Reichert JM. Antibodies to watch in 2016. mAbs 2016;8:197–204. doi:10.1080/19420862.2015.1125583
28
Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. mAbs 2015;7:9–14. doi:10.4161/19420862.2015.989042
29
Reichert JM. Marketed therapeutic antibodies compendium. mAbs 2012;4:413–5. doi:10.4161/mabs.19931
30
Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Therapy 2002;9:967–78. doi:10.1038/sj.cgt.7700537
31
Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. Nature Biotechnology 2012;30:658–70. doi:10.1038/nbt.2287
32
Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nature Reviews Drug Discovery 2015;14:642–62. doi:10.1038/nrd4663
33
Larson C, Oronsky B, Scicinski J, et al. Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget 2015;6. doi:10.18632/oncotarget.5116
34
Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Reviews Immunology 2012;12:269–81. doi:10.1038/nri3191
35
Gill S, June CH. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunological Reviews 2015;263:68–89. doi:10.1111/imr.12243
36
Barrett DM, Grupp SA, June CH. Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street. The Journal of Immunology 2015;195:755–61. doi:10.4049/jimmunol.1500751
37
Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nature Reviews Cancer 2012;12:265–77. doi:10.1038/nrc3258